Oncology Peer Review On-The-Go: 1-on-1 with Dr. Xu Ji: Mental Health Among Cancer Survivors

Podcast

In the newest episode of Oncology Peer Review On-The-Go, CancerNetwork speaks with Xu Ji, PhD, MSPH, of the Winship Cancer Institute about her research on the topic of adult cancer survivorship and mental health.

In this episode of Oncology Peer Review On-The-Go, CancerNetwork speaks 1-on-1 with Xu Ji, PhD, MSPH, of the Winship Cancer Institute regarding her research entitled "Mental Health Among Nonelderly Adult Cancer Survivors: A National Estimate."

Subscribe to the Oncology Peer Review On-The-Go podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

Recent Videos
The clinical adoption of twice-daily accelerated radiotherapy has been limited in North America despite improved outcomes, according to Bin Gui, MD.
4 experts in this video
4 experts in this video
7 experts are featured in this series.
The development of multimodal biomarkers may help predict response to immunotherapy among patients with melanoma and other malignancies.
Related Content
Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.

Exploring T-Cell Engager Use in Chemotherapy-Resistant ES-SCLC

Roman Fabbricatore
September 30th 2025
Article

Biomarker research may better elucidate clinical benefit and identify mechanisms of resistance with tarlatamab in extensive-stage small cell lung cancer.

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Gemcitabine Intravesical System Offers Tremendous Benefits in NMIBC

Gary Steinberg, MD
September 29th 2025
Podcast

Prospective data observed with the gemcitabine intravesical system may be superior to prior reports of other therapies in BCG-unresponsive NMIBC.

Overall urinary toxicity was not significantly improved with SBRT vs moderately hypofractionated IMRT.

SBRT Reduces Bowel Toxicity vs IMRT in Intermediate-Risk Prostate Cancer

Tim Cortese
September 30th 2025
Article

SBRT achieved a 5-year DFS of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate risk prostate cancer.

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Diving Into the Practical Applications of ctDNA in Oncology Care

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Arnab Basu, MBBS, MPH, FACP
September 25th 2025
Podcast

Experts discuss key considerations for applying ctDNA to clinical practice, such as distinguishing between tumor-informed and tumor-uninformed testing.

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

Radiation Shows Similar 10-Year Outcomes Vs Surgery in Early-Stage NSCLC

Russ Conroy
September 30th 2025
Article

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.

Anito-cel Yields Enduring Efficacy in Relapsed/Refractory Multiple Myeloma

Russ Conroy
September 30th 2025
Article

Treatment with anito-cel shows a predictable and manageable safety profile among those with relapsed/refractory multiple myeloma in the iMMagine-1 trial.